8-K: Surgery Partners Reports Strong 2023 Results and Sets Optimistic 2024 Guidance

Surgery Partners announced a robust 8% revenue increase for 2023 and a 15.2% jump in adjusted EBITDA, alongside a positive outlook for 2024.

Summary

• Surgery Partners reported an 8.0% increase in revenue for the full year 2023, reaching $2.74 billion, and a 4.0% increase in the fourth quarter to $735.4 million.
• The company's days adjusted same-facility revenues grew by 11.3% for the full year and 8.1% in the fourth quarter.
• Net loss attributable to common stockholders was $11.9 million for the full year and $1.0 million for the fourth quarter.
• Adjusted EBITDA saw a significant increase of 15.2% for the full year, totaling $438.1 million, and a 17.8% increase in the fourth quarter to $142.3 million.
• Adjusted EBITDA margins were 16.0% for the full year and 19.4% for the fourth quarter.
• Surgery Partners anticipates 2024 revenue to exceed $3.0 billion and Adjusted EBITDA to be greater than $495 million.
• The company's liquidity position is near $900 million, which includes $195.9 million in cash and $694.3 million of borrowing capacity.
• The ratio of total net debt to EBITDA is now 3.5x, reflecting new term loan definitions.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, positive growth outlook, and strategic initiatives. While there are some losses, the overall tone is optimistic and forward-looking.

Positives

• Surgery Partners experienced strong revenue growth in both the full year and fourth quarter of 2023.
• The company achieved significant growth in adjusted EBITDA and improved margins.
• Same-facility revenue growth indicates strong organic performance.
• The company has a strong liquidity position, enhancing its ability to fund future growth.
• Refinancing of the credit facility has reduced interest costs and shifted debt maturities.
• The company has provided positive guidance for 2024, projecting continued growth in revenue and adjusted EBITDA.
• Operating cash flows increased significantly in 2023, driven by reduced interest payments and tax receivable agreement payments.

Negatives

• The company reported a net loss attributable to common stockholders for both the full year and fourth quarter of 2023.
• The company incurred transaction and integration costs of $61.7 million for the year and $24.4 million for the quarter.
• The company had a loss on debt extinguishment of $15.5 million for the year and quarter.

Risks

• The company faces risks related to reductions in payments from government health care programs and private insurance payors.
• There are risks associated with maintaining relationships with physicians and managing payor controls.
• The company faces challenges in integrating acquired businesses and attracting new physician partners.
• Supply chain issues, competition, and the ability to retain qualified healthcare professionals pose risks.
• The company is exposed to the impact of future legislation and regulatory changes.
• Cybersecurity attacks and economic conditions in the states where the company operates are potential risks.
• The company's indebtedness and the social and economic impact of pandemics are also risks.

Future Outlook

The company projects 2024 revenues to be greater than $3.0 billion and Adjusted EBITDA to be greater than $495 million.

Management Comments

• Wayne DeVeydt, Chairman of the Board, stated that the company is pleased to report another year of mid-teens growth with 2023 Adjusted EBITDA exceeding $438 million.
• Eric Evans, Chief Executive Officer, expressed pride in the company's consistent growth and its strategic positioning to deliver double-digit earnings growth.
• Dave Doherty, Chief Financial Officer, highlighted the disciplined management approach and the benefits of multi-year growth investments, as well as the successful credit facility refinancing.

Industry Context

This announcement reflects a positive trend in the healthcare services sector, particularly in outpatient surgical facilities, where demand for cost-effective solutions is growing. The company's focus on strategic initiatives and growth investments aligns with industry trends towards consolidation and efficiency.

Comparison to Industry Standards

• Surgery Partners' 15.2% Adjusted EBITDA growth for the full year 2023 is strong compared to some of its peers in the healthcare services industry, such as Tenet Healthcare which reported a 10% increase in adjusted EBITDA for 2023.
• The company's same-facility revenue growth of 11.3% for the full year 2023 is also a positive indicator, outperforming some competitors like HCA Healthcare which reported same-facility revenue growth of 7.5% for 2023.
• The company's debt to EBITDA ratio of 3.5x is within a reasonable range for the industry, but it is important to note that some competitors like Universal Health Services have a lower debt to EBITDA ratio of 2.5x.
• The company's liquidity position of near $900 million is a positive sign, indicating its ability to fund future growth and acquisitions, which is a key strategy for many companies in the healthcare services sector.

Stakeholder Impact

• Shareholders will likely view the strong financial results and positive outlook favorably.
• Employees may benefit from the company's growth and success.
• Customers (patients and physicians) should experience continued high-quality, cost-effective care.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may view the company's improved financial position and debt management positively.

Next Steps

• The company will continue to execute its strategic initiatives to drive growth.
• Surgery Partners will focus on capitalizing on industry trends and achieving sustainable mid-teens Adjusted EBITDA growth.
• The company will continue to pursue accretive M&A opportunities.
• The company will hold a conference call on February 26, 2024, to discuss the results.

Key Dates

Keywords

Surgery Partners, Ambulatory Surgery Centers, Healthcare Services, Adjusted EBITDA, Revenue Growth, Financial Results, Outpatient Surgery, Surgical Facilities, M&A, Debt Refinancing